Development programme
SURMOUNT — tirzepatide in obesity
The phase 3 weight-management programme for the dual GIP and GLP-1 receptor agonist tirzepatide, including trials in participants with and without type 2 diabetes, a maintenance-withdrawal design and a dedicated obstructive sleep apnoea programme.
The phase 3 weight-management programme for the dual GIP and GLP-1 receptor agonist tirzepatide, including trials in participants with and without type 2 diabetes, a maintenance-withdrawal design and a dedicated obstructive sleep apnoea programme.
Sponsor class: Manufacturer-sponsored. First record: 2019.
Showing 0 records on this page
Records in this programme
26 documents · page 1 of 2
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SURMOUNT-1 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 2,539 | 2022 | High |
| SURMOUNT-2 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 938 | 2023 | High |
| SURMOUNT-3 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 806 | 2023 | High |
| SURMOUNT-4 | Tirzepatide | Phase 3 | Reported | Randomised withdrawal | 670 | 2024 | High |
| SURMOUNT-5 | Tirzepatide | Phase 3 | Reported | Randomised, open-label, active-controlled | 751 | 2025 | High |
| SURMOUNT-KOA | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Low |
| SURMOUNT-OSA-1 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | High |
| SURMOUNT-OSA-2 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | High |
| SURMOUNT-1-ELDERLYprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2022 | Very low |
| SURMOUNT-1-OLEprogramme record | Tirzepatide | Phase 3 | Reported | Single-arm open-label | — | 2022 | Very low |
| SURMOUNT-2-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| SURMOUNT-2-HEPATIC-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SURMOUNT-2-PKprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SURMOUNT-2-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SURMOUNT-3-BODY-COMPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| SURMOUNT-3-QOLprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| SURMOUNT-3-REGIONAL-JPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| SURMOUNT-4-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2024 | Very low |
| SURMOUNT-4-HEPATIC-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SURMOUNT-4-REGIONAL-CNprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURMOUNT-5-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| SURMOUNT-KOA-BODY-COMPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| SURMOUNT-KOA-REGIONAL-JPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| SURMOUNT-OSA-1-ELDERLYprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
page 1 of 2